Last $107.23 USD
Change Today +0.32 / 0.30%
Volume 632.0K
ALNY On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

alnylam pharmaceuticals inc (ALNY) Key Developments

Alnylam Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Alnylam Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

Alnylam Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:30 AM

Alnylam Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: John M. Maraganore, Chief Executive Officer and Executive Director.

Alnylam Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM

Alnylam Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

Alnylam Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Alnylam Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net revenues from collaborators of $24,019,000 compared with $10,847,000 for the same period a year ago. Loss from operations was $45,712,000 compared with $29,592,000 for the same period a year ago. Loss before income taxes was $43,480,000 compared with $29,336,000 for the same period a year ago. Net loss was $21,389,000 or $0.28 per basic and diluted share compared with $32,357,000 or $0.51 per basic and diluted share for the same period a year ago. Non-GAAP net loss was $21,389,000 or $0.28 per basic and diluted share compared with $32,357,000 or $0.51 per basic and diluted share for the same period a year ago. For the year, the company reported net revenues from collaborators of $50,561,000 compared with $47,167,000 for the same period a year ago. Loss from operations was $404,980,000 compared with $92,942,000 for the same period a year ago. Loss before income taxes was $400,604,000 compared with $91,920,000 for the same period a year ago. Net loss was $360,395,000 or $4.85 per basic and diluted share compared with $89,225,000 or $1.45 per basic and diluted share for the same period a year ago. Non-GAAP net loss was $139,629,000 or $1.88 per basic and diluted share compared with $89,225,000 or $1.45 per basic and diluted share for the same period a year ago.

Alnylam Pharmaceuticals, Inc. to Report Q4, 2014 Results on Feb 12, 2015

Alnylam Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $107.23 USD +0.32

ALNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.82 AUD -0.015
Enzon Pharmaceuticals Inc $1.12 USD 0.00
Galena Biopharma Inc $1.95 USD +0.10
Silence Therapeutics PLC 245.00 GBp +3.00
View Industry Companies
 

Industry Analysis

ALNY

Industry Average

Valuation ALNY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 162.7x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 163.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.